Myriad Genetics reported a year‑over‑year revenue decline in Q3 but outlined product launches it expects to drive growth, including an expanded MyRisk hereditary cancer panel, a Polaris prostate test combining molecular and AI inputs, and a tumor‑informed minimal residual disease (MRD) assay developed with Sophia Genetics slated for first half 2026. Management highlighted MyRisk share gains and a strategy that pairs core hereditary testing with precision oncology tools to offset coverage headwinds.